FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2101926814> ?p ?o ?g. }

• W2101926814 endingPage "e47485" @default.
• W2101926814 startingPage "e47485" @default.
• W2101926814 abstract "Background A new class of antiretrovirals, AntiViral-HyperActivation Limiting Therapeutics (AV-HALTs), has been proposed as a disease-modifying therapy to both reduce Human Immunodeficiency Virus Type 1 (HIV-1) RNA levels and the excessive immune activation now recognized as the major driver of not only the continual loss of CD4+ T cells and progression to Acquired Immunodeficiency Syndrome (AIDS), but also of the emergence of both AIDS-defining and non-AIDS events that negatively impact upon morbidity and mortality despite successful (ie, fully suppressive) therapy. VS411, the first-in-class AV-HALT, combined low-dose, slow-release didanosine with low-dose hydroxycarbamide to accomplish both objectives with a favorable toxicity profile during short-term administration. Five dose combinations were administered as VS411 to test the AV-HALT Proof-of-Concept in HIV-1-infected subjects. Methods Multinational, double-blind, 28-day Phase 2a dose-ranging Proof-of-Concept study of antiviral activity, immunological parameters, safety, and genotypic resistance in 58 evaluable antiretroviral-naïve HIV-1-infected adults. Randomization and allocation to study arms were carried out by a central computer system. Results were analyzed by ANOVA, Kruskal-Wallis, ANCOVA, and two-tailed paired t tests. Results VS411 was well-tolerated, produced significant reductions of HIV-1 RNA levels, increased CD4+ T cell counts, and led to significant, rapid, unprecedented reductions of immune activation markers after 28 days despite incomplete viral suppression and without inhibiting HIV-1-specific immune responses. The didanosine 200 mg/HC 900 mg once-daily formulation demonstrated the greatest antiviral efficacy (HIV-1 RNA: −1.47 log10 copies/mL; CD4+ T cell count: +135 cells/mm3) and fewest adverse events. Conclusions VS411 successfully established the Proof-of-Concept that AV-HALTs can combine antiviral efficacy with rapid, potentially beneficial reductions in the excessive immune system activation associated with HIV-1 disease. Rapid reductions in markers of immune system hyperactivation and cellular proliferation were obtained despite the fact that VS411 did not attain maximal suppression of HIV RNA, suggesting this effect was due to the HALT component. Trial Registration ITEudraCT 2007-002460-98" @default.
• W2101926814 created "2016-06-24" @default.
• W2101926814 creator A5014421603 @default.
• W2101926814 creator A5020004772 @default.
• W2101926814 creator A5021208069 @default.
• W2101926814 creator A5023639833 @default.
• W2101926814 creator A5028823785 @default.
• W2101926814 creator A5055370060 @default.
• W2101926814 creator A5056990629 @default.
• W2101926814 creator A5061097917 @default.
• W2101926814 creator A5073394725 @default.
• W2101926814 creator A5074537783 @default.
• W2101926814 date "2012-10-19" @default.
• W2101926814 modified "2023-10-05" @default.
• W2101926814 title "VS411 Reduced Immune Activation and HIV-1 RNA Levels in 28 Days: Randomized Proof-of-Concept Study for AntiViral-HyperActivation Limiting Therapeutics" @default.
• W2101926814 cites W1506762800 @default.
• W2101926814 cites W1541046939 @default.
• W2101926814 cites W1883001132 @default.
• W2101926814 cites W1969575774 @default.
• W2101926814 cites W1970394208 @default.
• W2101926814 cites W1974393084 @default.
• W2101926814 cites W1975804438 @default.
• W2101926814 cites W1980574126 @default.
• W2101926814 cites W1987145430 @default.
• W2101926814 cites W1992991204 @default.
• W2101926814 cites W2005218441 @default.
• W2101926814 cites W2005910303 @default.
• W2101926814 cites W2012976492 @default.
• W2101926814 cites W2017903057 @default.
• W2101926814 cites W2025373690 @default.
• W2101926814 cites W2029126048 @default.
• W2101926814 cites W2033021499 @default.
• W2101926814 cites W2052661376 @default.
• W2101926814 cites W2054825291 @default.
• W2101926814 cites W2058563502 @default.
• W2101926814 cites W2067547048 @default.
• W2101926814 cites W2077713919 @default.
• W2101926814 cites W2078552483 @default.
• W2101926814 cites W2091375096 @default.
• W2101926814 cites W2095401749 @default.
• W2101926814 cites W2097611785 @default.
• W2101926814 cites W2098999499 @default.
• W2101926814 cites W2105804574 @default.
• W2101926814 cites W2113177177 @default.
• W2101926814 cites W2122483069 @default.
• W2101926814 cites W2124554513 @default.
• W2101926814 cites W2124847351 @default.
• W2101926814 cites W2127578660 @default.
• W2101926814 cites W2128479250 @default.
• W2101926814 cites W2130305699 @default.
• W2101926814 cites W2131245007 @default.
• W2101926814 cites W2138694347 @default.
• W2101926814 cites W2140096403 @default.
• W2101926814 cites W2140573695 @default.
• W2101926814 cites W2141277501 @default.
• W2101926814 cites W2144361427 @default.
• W2101926814 cites W2144617044 @default.
• W2101926814 cites W2167056324 @default.
• W2101926814 cites W2325369502 @default.
• W2101926814 cites W2406257591 @default.
• W2101926814 cites W2406858656 @default.
• W2101926814 cites W51502992 @default.
• W2101926814 cites W76119661 @default.
• W2101926814 cites W2067971620 @default.
• W2101926814 cites W2412769044 @default.
• W2101926814 doi "https://doi.org/10.1371/journal.pone.0047485" @default.
• W2101926814 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3477169" @default.
• W2101926814 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23094055" @default.
• W2101926814 hasPublicationYear "2012" @default.
• W2101926814 type Work @default.
• W2101926814 sameAs 2101926814 @default.
• W2101926814 citedByCount "3" @default.
• W2101926814 countsByYear W21019268142013 @default.
• W2101926814 countsByYear W21019268142014 @default.
• W2101926814 crossrefType "journal-article" @default.
• W2101926814 hasAuthorship W2101926814A5014421603 @default.
• W2101926814 hasAuthorship W2101926814A5020004772 @default.
• W2101926814 hasAuthorship W2101926814A5021208069 @default.
• W2101926814 hasAuthorship W2101926814A5023639833 @default.
• W2101926814 hasAuthorship W2101926814A5028823785 @default.
• W2101926814 hasAuthorship W2101926814A5055370060 @default.
• W2101926814 hasAuthorship W2101926814A5056990629 @default.
• W2101926814 hasAuthorship W2101926814A5061097917 @default.
• W2101926814 hasAuthorship W2101926814A5073394725 @default.
• W2101926814 hasAuthorship W2101926814A5074537783 @default.
• W2101926814 hasBestOaLocation W21019268141 @default.
• W2101926814 hasConcept C126322002 @default.
• W2101926814 hasConcept C142462285 @default.
• W2101926814 hasConcept C159047783 @default.
• W2101926814 hasConcept C203014093 @default.
• W2101926814 hasConcept C2777447569 @default.
• W2101926814 hasConcept C2778366672 @default.
• W2101926814 hasConcept C2779134260 @default.
• W2101926814 hasConcept C2779316324 @default.
• W2101926814 hasConcept C2993143319 @default.
• W2101926814 hasConcept C3013748606 @default.
• W2101926814 hasConcept C71924100 @default.
• W2101926814 hasConcept C8891405 @default.

• next